Literature DB >> 11806471

Intensive insulin treatment in diabetic children.

J Ludvigsson1, G B Bolli.   

Abstract

Intensification of insulin therapy which maintains long-term near-normoglycaemia (HbA1c<7.0%) strongly protects against onset and/or progression of diabetic microangiopathy in Type 1 diabetes mellitus of adults. Similar intensification of insulin therapy is needed in diabetic children as well, in order to prevent complications a few years after diabetes onset, ie very often in young age. Provided adequate psychosocial support and education are available, children should be treated with multiple daily injections of insulin or, when necessary, with continuous subcutaneous insulin infusion, along with blood glucose monitoring. Insulin regimens may differ from child to child and vary from day to day in the same child, depending on lifestyle and considering all the available insulin preparations. These include the short-acting insulin (both human regular and short-acting insulin analogues), the intermediate-acting insulin (NPH and Lente), as well as the new long-acting insulin analogue glargine. The latter seems a promising candidate to substitute of basal insulin. The concern that intensified insulin therapy increases the risk of hypoglycaemia, as indicated by the Diabetes Control and Complications Trial (DCCT), is no longer tenable. On the contrary, a physiological, flexible insulin regimen better than a fixed insulin regimen, usually the twice daily split-mixed regimen, protects against the risk of hypoglycaemia in relation to food ingestion, physical exercise and sleep. Thus, appropriate education should be delivered at diabetes onset to the child and parents in order to start the strategy of intensified insulin therapy as early as possible.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11806471

Source DB:  PubMed          Journal:  Diabetes Nutr Metab        ISSN: 0394-3402


  8 in total

Review 1.  Islet transplant: an option for childhood diabetes?

Authors:  E Hathout; J Lakey; J Shapiro
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

2.  Prevention of severe hypoglycaemia in type I diabetes: a randomised controlled population study.

Authors:  S Nordfeldt; C Johansson; E Carlsson; J-A Hammersjö
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

3.  Basal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin.

Authors:  R Schiaffini; P I Patera; C Bizzarri; P Ciampalini; M Cappa
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

4.  As Facts and Chats Go Online, What Is Important for Adolescents with Type 1 Diabetes?

Authors:  Sam Nordfeldt; Teresia Angarne-Lindberg; Maria Nordwall; Joakim Ekberg; Carina Berterö
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

5.  Use of a web 2.0 portal to improve education and communication in young patients with families: randomized controlled trial.

Authors:  Lena Hanberger; Johnny Ludvigsson; Sam Nordfeldt
Journal:  J Med Internet Res       Date:  2013-08-23       Impact factor: 5.428

6.  Health professionals' attitudes towards using a Web 2.0 portal for child and adolescent diabetes care: qualitative study.

Authors:  Cecilia Nordqvist; Lena Hanberger; Toomas Timpka; Sam Nordfeldt
Journal:  J Med Internet Res       Date:  2009-04-06       Impact factor: 5.428

7.  Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.

Authors:  N Thalange; A Bereket; J Larsen; L C Hiort; V Peterkova
Journal:  Diabet Med       Date:  2013-02       Impact factor: 4.359

8.  Evaluation of the correlation between type 1 diabetes and cognitive function in children and adolescents, and comparison of this correlation with structural changes in the central nervous system: a study protocol.

Authors:  Ata Pourabbasi; Mehdi Tehrani-Doost; Soqra Ebrahimi Qavam; Bagher Larijani
Journal:  BMJ Open       Date:  2016-04-28       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.